JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.51 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $476,000 | +9.2% | 10,407 | +7.0% | 0.00% | – |
| Q3 2017 | $436,000 | +57.4% | 9,728 | +5.2% | 0.00% | – |
| Q2 2017 | $277,000 | -39.0% | 9,248 | -54.8% | 0.00% | – |
| Q1 2017 | $454,000 | +57.6% | 20,463 | +42.3% | 0.00% | – |
| Q4 2016 | $288,000 | -32.6% | 14,379 | +1.0% | 0.00% | – |
| Q3 2016 | $427,000 | +42600.0% | 14,238 | +37368.4% | 0.00% | – |
| Q2 2016 | $1,000 | -99.9% | 38 | -99.8% | 0.00% | – |
| Q1 2016 | $816,000 | +1940.0% | 21,400 | +2277.8% | 0.00% | – |
| Q4 2015 | $40,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |